These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12748310)

  • 1. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival.
    Whitehead CM; Earle KA; Fetter J; Xu S; Hartman T; Chan DC; Zhao TL; Piazza G; Klein-Szanto AJ; Pamukcu R; Alila H; Bunn PA; Thompson WJ
    Mol Cancer Ther; 2003 May; 2(5):479-88. PubMed ID: 12748310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
    Chan DC; Earle KA; Zhao TL; Helfrich B; Zeng C; Baron A; Whitehead CM; Piazza G; Pamukcu R; Thompson WJ; Alila H; Nelson P; Bunn PA
    Clin Cancer Res; 2002 Mar; 8(3):904-12. PubMed ID: 11895925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.
    Piazza GA; Thompson WJ; Pamukcu R; Alila HW; Whitehead CM; Liu L; Fetter JR; Gresh WE; Klein-Szanto AJ; Farnell DR; Eto I; Grubbs CJ
    Cancer Res; 2001 May; 61(10):3961-8. PubMed ID: 11358813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
    Witta SE; Gustafson DL; Pierson AS; Menter A; Holden SN; Basche M; Persky M; O'Bryant CL; Zeng C; Baron A; Long ME; Gibbs A; Kelly K; Bunn PA; Chan DC; Pallansch P; Eckhardt SG
    Clin Cancer Res; 2004 Nov; 10(21):7229-37. PubMed ID: 15534096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.
    Bunn PA; Chan DC; Earle K; Zhao TL; Helfrich B; Kelly K; Piazza G; Whitehead CM; Pamukcu R; Thompson W; Alila H
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):87-94. PubMed ID: 11894018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer.
    Jones SF; Kuhn JG; Greco FA; Raefsky EL; Hainsworth JD; Dickson NR; Thompson DS; Willcutt NT; White MB; Burris HA
    Clin Lung Cancer; 2005 May; 6(6):361-6. PubMed ID: 15943897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer.
    Ichite N; Chougule MB; Jackson T; Fulzele SV; Safe S; Singh M
    Clin Cancer Res; 2009 Jan; 15(2):543-52. PubMed ID: 19147759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin.
    Thompson WJ; Piazza GA; Li H; Liu L; Fetter J; Zhu B; Sperl G; Ahnen D; Pamukcu R
    Cancer Res; 2000 Jul; 60(13):3338-42. PubMed ID: 10910034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.
    Drugs R D; 2004; 5(4):220-6. PubMed ID: 15230629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
    Weiss GJ; Vokes EE; Bunn PA; Magree L; Rusk J; Albert D; Kelly K
    J Thorac Oncol; 2007 Oct; 2(10):933-8. PubMed ID: 17909356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors.
    Fulzele SV; Chatterjee A; Shaik MS; Jackson T; Ichite N; Singh M
    Anticancer Drugs; 2007 Jan; 18(1):65-78. PubMed ID: 17159504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells.
    Liu L; Li H; Underwood T; Lloyd M; David M; Sperl G; Pamukcu R; Thompson WJ
    J Pharmacol Exp Ther; 2001 Nov; 299(2):583-92. PubMed ID: 11602670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells.
    Pitari GM; Li T; Baksh RI; Waldman SA
    Mol Cancer Ther; 2006 May; 5(5):1190-6. PubMed ID: 16731751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
    Ryan CW; Stadler WM; Vogelzang NJ
    BJU Int; 2005 May; 95(7):963-8. PubMed ID: 15839914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel and exisulind in hormone-refractory prostate cancer.
    Ryan CW; Stadler WM; Vogelzang NJ
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):56-61. PubMed ID: 11685730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulindac and its derivatives: a novel class of anticancer agents.
    Haanen C
    Curr Opin Investig Drugs; 2001 May; 2(5):677-83. PubMed ID: 11569947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation.
    Li H; Liu L; David ML; Whitehead CM; Chen M; Fetter JR; Sperl GJ; Pamukcu R; Thompson WJ
    Biochem Pharmacol; 2002 Nov; 64(9):1325-36. PubMed ID: 12392815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-tocopheryl succinate sensitizes human colon cancer cells to exisulind-induced apoptosis.
    Lim SJ; Lee YJ; Park DH; Lee E; Choi MK; Park W; Chun KH; Choi HG; Cho JS
    Apoptosis; 2007 Feb; 12(2):423-31. PubMed ID: 17191116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
    Mahaffey CM; Davies AM; Lara PN; Pryde B; Holland W; Mack PC; Gumerlock PH; Gandara DR
    Clin Lung Cancer; 2007 Nov; 8(9):548-53. PubMed ID: 18186959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites.
    Rice PL; Goldberg RJ; Ray EC; Driggers LJ; Ahnen DJ
    Cancer Res; 2001 Feb; 61(4):1541-7. PubMed ID: 11245463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.